| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/20/2000 | WO2000042020A1 Phenylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | WO2000042019A1 6-arylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | WO2000042018A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | WO2000042011A1 Amide compounds |
| 07/20/2000 | WO2000042003A1 Benzenesulfonamide derivatives and their use as mek inhibitors |
| 07/20/2000 | WO2000042002A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| 07/20/2000 | WO2000041994A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| 07/20/2000 | WO2000041705A1 Pre-conditioning against cell death |
| 07/20/2000 | WO2000041700A1 Use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of cerebral degenerative disorders |
| 07/20/2000 | WO2000041697A1 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia |
| 07/20/2000 | WO2000041696A1 Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances |
| 07/20/2000 | WO2000041684A1 A pharmaceutical combination for the treatment of depression |
| 07/20/2000 | WO2000041683A2 Transdermal therapeutic system with self-adhesive matrix, containing organic acid addition salts of morphine- or morphinan-type alkaloids |
| 07/20/2000 | WO2000041681A2 MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST |
| 07/20/2000 | WO2000041566A1 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 07/20/2000 | WO2000041545A2 Regulators of the pct or smoothened pathway, compositions and uses related thereto |
| 07/20/2000 | WO2000041505A2 Anthranilic acid derivatives |
| 07/20/2000 | WO2000041484A2 Novel use of phospholipids of vegetable and animal origin in nutritional therapy |
| 07/20/2000 | WO2000041472A2 Binding partners for 5-ht5-receptors for the treatment of migraine |
| 07/20/2000 | WO2000021521A3 Sertraline oral concentrate |
| 07/20/2000 | WO2000020590A3 G-protein coupled receptor proteins |
| 07/20/2000 | WO2000019985A3 New sustained release oral formulations |
| 07/20/2000 | WO2000017358A3 Human chaperone proteins |
| 07/20/2000 | WO2000016800A3 Methods of treating chronic pain |
| 07/20/2000 | WO2000014097A3 Novel pyranoses |
| 07/20/2000 | WO2000014064A3 Gaba uptake inhibitors having a pyrrolidine structure |
| 07/20/2000 | WO2000002897A9 Delta cleavage products and methods based thereon |
| 07/20/2000 | DE19901687A1 Opioide Analgetika mit kontrollierter Wirkstofffreisetzung Opioid analgesics controlled release |
| 07/20/2000 | DE19901683A1 Analgetikum mit kontrollierter Wirkstofffreisetzung Analgesic with controlled release of active ingredient |
| 07/20/2000 | DE19855704A1 Mittel zur Behandlung der Symptome der Parkinsonschen Krankheit Agents for treating the symptoms of Parkinson's disease |
| 07/20/2000 | CA2370042A1 Regulators of the pct or smoothened pathway, compositions and uses related thereto |
| 07/20/2000 | CA2360588A1 Human homologues of proteins regulated by circadian rhythms |
| 07/20/2000 | CA2360386A1 Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | CA2360268A1 Pre-conditioning against cell death |
| 07/20/2000 | CA2359990A1 Novel aralkyl amines of spirofuropyridines useful in therapy |
| 07/20/2000 | CA2359986A1 2,3-o-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors |
| 07/20/2000 | CA2359980A1 Derivatives of monosaccharides as cell adhesion inhibitors |
| 07/20/2000 | CA2359952A1 Triazole compounds with dopamine-d3-receptor affinity |
| 07/20/2000 | CA2359942A1 Triazole compounds with dopamine-d3-receptor affinity |
| 07/20/2000 | CA2359562A1 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| 07/20/2000 | CA2359504A1 Novel compounds |
| 07/20/2000 | CA2359479A1 Novel complex-forming proteins |
| 07/20/2000 | CA2359416A1 6-arylphenanthridines with pde-iv inhibiting activity |
| 07/20/2000 | CA2359390A1 Utilisation of 2-substituted 1,2-benzisothiazole derivatives and 3-substituted tetrahydropyridopyrimidinone derivatives for the prophylaxis and therapy of cerebral ischaemia |
| 07/20/2000 | CA2359349A1 A method for introducing substances into cells, and use of said method |
| 07/20/2000 | CA2359273A1 Pharmaceutical formulations containing an opioid and an .alpha.-agonist |
| 07/20/2000 | CA2358693A1 Anti-ccr4 antibodies and methods of use therefor |
| 07/20/2000 | CA2355374A1 1-heterocycle substituted diarylamines |
| 07/20/2000 | CA2349832A1 Benzenesulfonamide derivatives and their use as mek inhibitors |
| 07/20/2000 | CA2349467A1 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
| 07/20/2000 | CA2349180A1 Anthranilic acid derivatives |
| 07/20/2000 | CA2348236A1 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| 07/19/2000 | EP1020470A2 Galanthamine derivatives, a process for their preparation and their use as medicaments |
| 07/19/2000 | EP1020469A2 Galanthamine derivatives, a process for their preparation and their use as medicaments |
| 07/19/2000 | EP1020464A1 Paroxetine methansulfonate |
| 07/19/2000 | EP1020463A1 Paroxetine methanesulfonate |
| 07/19/2000 | EP1020187A1 Pharmaceutical compositions containing hydroximic acid derivatives |
| 07/19/2000 | EP1020185A2 Opioid analgesics with controlled release |
| 07/19/2000 | EP1020183A2 Analgesic composition with controlled release |
| 07/19/2000 | EP1019716A1 Methods for screening drugs to predict tardive dyskinesia |
| 07/19/2000 | EP1019506A1 101 human secreted proteins |
| 07/19/2000 | EP1019434A2 Inhibitors of metalloproteinases, their therapeutic use, and process for the production of the starting compound in their synthesis |
| 07/19/2000 | EP1019427A1 N?6 -substituted-adenosine-5'-uronamides as adenosine receptor modulators |
| 07/19/2000 | EP1019412A1 Biphenyl(thio)amide and biphenylethan(thi)one derivatives, their preparation and their use as 5-ht 1d? receptor antagonists |
| 07/19/2000 | EP1019410A1 Spiro-piperidine derivatives and their use as tachykinin antagonists |
| 07/19/2000 | EP1019409A1 Poly(adp-ribose) polymerase ("parp") inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| 07/19/2000 | EP1019408A1 1,2,3,4-TETRAHYDRO-BENZOFURO 3,2-c]PYRIDINE DERIVATIVES-- |
| 07/19/2000 | EP1019396A1 Novel cycloalkyl substituted imidazoles |
| 07/19/2000 | EP1019380A2 Tricyclic 3-oxo-propanenitrile compounds |
| 07/19/2000 | EP1019374A1 Polymorphs of donepezil hydrochloride and process for production |
| 07/19/2000 | EP1019373A1 Novel human nk 3? receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them |
| 07/19/2000 | EP1019372A1 Novel fused pyrrolecarboxamides; a new class of gaba brain receptor ligands |
| 07/19/2000 | EP1019360A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 07/19/2000 | EP1019088A1 Composition for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug |
| 07/19/2000 | EP1019081A2 Apolipoprotein e/growth factor complexes and methods of use |
| 07/19/2000 | EP1019079A1 Modulation of nitric oxide production |
| 07/19/2000 | EP1019075A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 07/19/2000 | EP1019072A1 Method for assisting in differential diagnosis and treatment of autistic syndromes |
| 07/19/2000 | EP1019071A2 Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods |
| 07/19/2000 | EP1019069A2 Novel methods for testing inhibitors of paired helical filaments and uses for treatment of alzheimer's disease |
| 07/19/2000 | EP1019057A1 A method of preventing or treating estrogen-dependent diseases and disorders |
| 07/19/2000 | EP1019044A1 Composition and methods for treating alzheimer's disease and other amyloidoses |
| 07/19/2000 | EP1019041A1 Method of improving disturbed behavior and elevating mood in humans |
| 07/19/2000 | EP1019040A1 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
| 07/19/2000 | EP1018880A1 2-methyl-thieno-benzodiazepine formulation |
| 07/19/2000 | EP1018878A1 Novel indolecarboxamides, pharmaceutical compositions and methodsof inhibiting calpain |
| 07/19/2000 | EP0821682B1 Benzimidazole compounds and their use as modulators of the gaba-a receptor complex |
| 07/19/2000 | EP0760819B1 Tricyclic dicarbonyl derivatives |
| 07/19/2000 | EP0573565B1 Opiate receptor antagonist modulates hyperkinetic movement disorder |
| 07/19/2000 | CN1260797A 3-substituted 3,4-dihydro-thieno (2,3-d) pyrimidine derivatives and preparation and use of same |
| 07/19/2000 | CN1260795A Quaternary ammonium compounds as tachykinin antagenists |
| 07/19/2000 | CN1260794A 5-aryl-3-(8-azabicyclo (3.2.2) oct-3-yl)-1,3,4-oxadiazol-2(3H)-one derivatives as -5HT4 receptor ligands |
| 07/19/2000 | CN1260792A Treatment of central nervous system disorders with selective estrogen receptor modulators |
| 07/19/2000 | CN1260791A 3-benzylpiperidine |
| 07/19/2000 | CN1260789A Heterocyclic compounds, method for preparing and medicine compositions containing same |
| 07/19/2000 | CN1260784A Quinoline derivatives as PDEIV and INF inhibitors |
| 07/19/2000 | CN1260781A Indole derivatives having combined 5HT1A, 5HT1B and 5HT1D receptor antagoinist activity |
| 07/19/2000 | CN1260717A Use of 1-ar (alk)yl-imidazoline-2-one for treating anxietyand stress conditions |
| 07/19/2000 | CN1260210A Traditional Chinese medicine for treating ischialgia neuralgia |
| 07/19/2000 | CN1260200A Traditional Chinese medicine compound medicine for giving-up drug-taking and its compounding method |